Hakutulokset - Semiond, Dorothée

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors Tekijä Ferron, Géraldine M., Dai, Yang, Semiond, Dorothée

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Preclinical profile of cabazitaxel Tekijä Vrignaud, Patricia, Semiond, Dorothée, Benning, Veronique, Beys, Eric, Bouchard, Hervé, Gupta, Sunil

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats Tekijä Cisternino, Salvatore, Bourasset, Fanchon, Archimbaud, Yves, Sémiond, Dorothée, Sanderink, Gérard, Scherrmann, Jean-Michel

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours Tekijä Fumoleau, Pierre, Trigo, Jose Manuel, Isambert, Nicolas, Sémiond, Dorothée, Gupta, Sunil, Campone, Mario

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients Tekijä Fau, Jean‐Baptiste, El‐Cheikh, Raouf, Brillac, Claire, Koiwai, Kimiko, Mace, Nathalie, Campana, Frank, Semiond, Dorothee, Nguyen, Laurent

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone Tekijä Thai, Hoai‐Thu, Gaudel, Nadia, Cerou, Marc, Ayral, Geraldine, Fau, Jean‐Baptiste, Sebastien, Bernard, van de Velde, Helgi, Semiond, Dorothée, Veyrat‐Follet, Christine

Hae kokoteksti Hae kokoteksti Hae kokoteksti

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma Tekijä Mikhael, Joseph, Richardson, Paul, Usmani, Saad Z., Raje, Noopur, Bensinger, William, Karanes, Chatchada, Campana, Frank, Kanagavel, Dheepak, Dubin, Franck, Liu, Qianying, Semiond, Dorothée, Anderson, Kenneth

Hae kokoteksti Hae kokoteksti Hae kokoteksti

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma Tekijä Koiwai, Kimiko, El‐Cheikh, Raouf, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean‐Baptiste, Veyrat‐Follet, Christine, Risse, Marie‐Laure, van de Velde, Helgi, Semiond, Dorothée, Nguyen, Laurent

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myelom... Tekijä Rachedi, Fatiha, Koiwai, Kimiko, Gaudel‐Dedieu, Nadia, Sebastien, Bernard, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean Baptiste, Nguyen, Laurent, van de Velde, Helgi, Veyrat‐Follet, Christine, Semiond, Dorothée

Hae kokoteksti Hae kokoteksti Hae kokoteksti

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis Tekijä Dimopoulos, Meletios A., Leleu, Xavier, Moreau, Philippe, Richardson, Paul G., Liberati, Anna Marina, Harrison, Simon J., Miles Prince, H., Ocio, Enrique M., Assadourian, Sylvie, Campana, Frank, Malinge, Laure, Sémiond, Dorothée, van de Velde, Helgi, Yong, Kwee

Hae kokoteksti Hae kokoteksti Hae kokoteksti

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab Tekijä Mikhael, Joseph, Belhadj-Merzoug, Karim, Hulin, Cyrille, Vincent, Laure, Moreau, Philippe, Gasparetto, Cristina, Pour, Ludek, Spicka, Ivan, Vij, Ravi, Zonder, Jeffrey, Atanackovic, Djordje, Gabrail, Nashat, Martin, Thomas G., Perrot, Aurore, Bensfia, Samira, Weng, Qilong, Brillac, Claire, Semiond, Dorothée, Macé, Sandrine, Corzo, Kathryn P., Leleu, Xavier

Hae kokoteksti Hae kokoteksti Hae kokoteksti